Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc. has demonstrated strong revenue growth, with a notable 21% increase in international osteoarthritis (OA) pain revenue and a 25% growth in its regenerative solutions segment, attributed mainly to the successful Integrity patch. The company has solidified its market position, with expectations to more than double procedures and revenue by 2025, indicating a promising expansion in its customer base and surgical applications. Additionally, improvements in key product measures and anticipated enhancements in gross margins suggest a favorable trajectory for overall financial performance in the upcoming quarters.

Bears say

Anika Therapeutics, Inc. reported a revenue decline of 5.9% year-over-year, generating $27.8 million, which reflects challenges in sustaining growth in its commercial and OEM channels. The company's gross margin fell short of expectations at 56%, primarily due to ongoing production yield issues, and its adjusted EBITDA of $0.9 million was below the anticipated $1.6 million, highlighting operational inefficiencies. Additionally, the failure of the pivotal FastTrack trial for Hyalofast to meet its primary endpoints raises concerns about the efficacy of its product pipeline, posing further risks to future revenue growth.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.